What is the role of SGLT2 inhibitors in heart failure patients and what adverse effects require monitoring?

• A. Only lower blood glucose without cardiovascular effects.
• B. Improve kidney function independent of glycemic status but do not cause infections.
• C. Provide cardio-renal benefits independent of glycemic status; monitor for volume depletion, genital mycotic infections, and rare ketoacidosis.
• D. Are contraindicated in heart failure.

Answer: (C)

SGLT2 inhibitors in heart failure provide cardio-renal benefits that go beyond lowering blood glucose, and these benefits occur regardless of whether the patient has diabetes. Large trials in both reduced and preserved ejection fraction show fewer heart failure hospitalizations and improved cardiovascular outcomes, and they also tend to protect kidney function by slowing progression of chronic kidney disease. The mechanism isn’t just glucose control; it includes osmotic diuresis and natriuresis that reduce volume overload and preload, stabilize renal hemodynamics, and may favorably influence cardiac remodeling and overall myocardial efficiency. Because these benefits apply independently of glycemic status, they’re useful for heart failure patients who do or do not have diabetes.

Adverse effects to monitor include volume depletion and potential hypotension from the diuretic-like effect, which can be more pronounced in patients with low intake or concurrent diuretics; genital mycotic infections due to glycosuria; and, although rare, ketoacidosis that can occur with normal or only mildly elevated glucose levels, especially in the setting of dehydration, acute illness, or reduced insulin. It’s important to check kidney function and electrolytes periodically and to educate patients about recognizing signs of DKA.

This is why these agents are described as providing cardio-renal benefits independent of glycemic status and why monitoring for volume status, genital infections, and rare ketoacidosis is essential.